Quick Answer
Zomedica Corp. reported Total Revenue of $32.03 million for fiscal year 2025.
Zomedica Corp. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $32.03M +17.4% |
$27.29M +8.3% |
$25.19M +33.0% |
$18.93M +358.0% |
$4.13M | $0.00 |
| Revenue (ASC 606) | $32.03M +17.4% |
$27.29M +8.3% |
$25.19M +33.0% |
$18.93M +358.0% |
$4.13M | $0.00 |
| Net Income | -$81.86M -74.2% |
-$46.98M -36.1% |
-$34.53M -102.9% |
-$17.02M +7.4% |
-$18.38M -8.7% |
-$16.91M +14.5% |
| Diluted EPS | -$0.08 -60.0% |
-$0.05 -25.0% |
-$0.04 -135.3% |
-$0.02 | — | — |
| Total Assets | $127.04M -38.7% |
$207.36M -18.1% |
$253.20M -9.4% |
$279.61M -0.3% |
$280.40M +323.9% |
$66.14M +1481.3% |
| Cash and Equivalents | $9.02M +28.4% |
$7.02M -45.8% |
$12.95M -52.7% |
$27.40M -85.9% |
$194.95M +214.5% |
$61.99M +12041.3% |
| Stockholders Equity | $115.40M -41.0% |
$195.66M -18.5% |
$240.02M -10.2% |
$267.39M -1.3% |
$270.89M +430.4% |
$51.07M +2337.2% |
| R&D Expense | $7.17M -1.4% |
$7.27M +26.5% |
$5.74M +122.8% |
$2.58M +54.1% |
$1.67M -79.2% |
$8.04M -22.2% |
| Operating Income | -$84.35M -65.2% |
-$51.05M -18.0% |
-$43.27M -97.4% |
-$21.92M -2.6% |
-$21.37M -27.5% |
-$16.76M +15.3% |
| Gross Profit | $21.68M +13.6% |
$19.09M +10.2% |
$17.32M +28.6% |
$13.47M +341.0% |
$3.05M | $0.00 |
| Shares Outstanding | 979.95M +0.0% |
979.95M +0.0% |
979.95M +0.0% |
979.95M +0.0% |
979.90M +52.6% |
642.04M +494.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $8.10M | +15.7% | +16.2% |
| Revenue (ASC 606) | September 30, 2025 | $8.10M | +15.7% | +16.2% |
| Net Income | September 30, 2025 | -$6.12M | +8.6% | +17.3% |
| Diluted EPS | September 30, 2025 | -$0.01 | +0.0% | +0.0% |
| Total Assets | September 30, 2025 | $130.91M | -38.9% | -4.1% |
| Cash and Equivalents | September 30, 2025 | $7.50M | -23.1% | -7.8% |
| Stockholders Equity | September 30, 2025 | $119.69M | -41.0% | -4.5% |
| R&D Expense | September 30, 2025 | $1.78M | -3.3% | -5.4% |
| Operating Income | September 30, 2025 | -$6.61M | +11.2% | +17.8% |
| Gross Profit | September 30, 2025 | $5.44M | +7.4% | +16.5% |
| Shares Outstanding | September 30, 2025 | 979.95M | +0.0% | +0.0% |
- Zomedica Corp. reported Total Revenue of $32.03 million for fiscal year 2025.
- Zomedica Corp. showed an increase of +17.4% in Total Revenue compared to the prior fiscal year.
- Zomedica Corp. reported Revenue (ASC 606) of $32.03 million for fiscal year 2025.
- Zomedica Corp. showed an increase of +17.4% in Revenue (ASC 606) compared to the prior fiscal year.
- Zomedica Corp. reported Net Income of -$81.86 million for fiscal year 2025.
- Zomedica Corp. showed a decrease of -74.2% in Net Income compared to the prior fiscal year.
- Zomedica Corp. reported Diluted EPS of $0.08 per share (loss) for fiscal year 2025.
- Zomedica Corp. showed a decrease of -60.0% in Diluted EPS compared to the prior fiscal year.
- Zomedica Corp. reported Total Assets of $127.04 million for fiscal year 2025.
- Zomedica Corp. showed a decrease of -38.7% in Total Assets compared to the prior fiscal year.
- Zomedica Corp. reported Cash and Equivalents of $9.02 million for fiscal year 2025.
- Zomedica Corp. showed an increase of +28.4% in Cash and Equivalents compared to the prior fiscal year.
- Zomedica Corp. reported Stockholders Equity of $115.40 million for fiscal year 2025.
- Zomedica Corp. showed a decrease of -41.0% in Stockholders Equity compared to the prior fiscal year.
- Zomedica Corp. reported R&D Expense of $7.17 million for fiscal year 2025.
- Zomedica Corp. showed a decrease of -1.4% in R&D Expense compared to the prior fiscal year.
- Zomedica Corp. reported Operating Income of -$84.35 million for fiscal year 2025.
- Zomedica Corp. showed a decrease of -65.2% in Operating Income compared to the prior fiscal year.
- Zomedica Corp. reported Gross Profit of $21.68 million for fiscal year 2025.
- Zomedica Corp. showed an increase of +13.6% in Gross Profit compared to the prior fiscal year.
- Zomedica Corp. reported Shares Outstanding of 979.95 million shares for fiscal year 2025.
- Zomedica Corp. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: